Drug and Therapeutics Bulletin 1995;33:92-93; doi:10.1136/dtb.1995.331292
Copyright © 1995 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Co-trimoxazole use restricted

Relevant BNF section: 5.1.8

Co-trimoxazole, the fixed-dose preparation of trimethoprim (80mg) plus sulphamethoxazole (400mg), has been available in the UK since 1969. At its launch the Drug and Therapeutics Bulletin accepted the logic of using the combination¹ but advised prescribers to be alert to the possibility of unwanted effects. In 1980 we advised that, in some infections, a single antibiotic might be at least as effective as co-trimoxazole, with a lower risk of unwanted effects.² Later that year, when trimethoprim became available alone, we recommended it should be used in the place of co-trimoxazole for uncomplicated infections of the urinary tract,³ advice we repeated in 1986.⁴ In July of this year, the licensed indications for co-trimoxazole were narrowed⁵ and now reflect many of our earlier recommendations. In this article we review the history of co-trimoxazole, discuss the recent licensing changes and ask when the drug should be used in clinical practice.

This article has been cited by other articles:

				V. I. Enne, P. M. Bennett, D. M. Livermore, and L. M. C. Hall Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure J. Antimicrob. Chemother., June 1, 2004; 53(6): 958 - 963. [Abstract] [Full Text] [PDF]

				R. F. Miller, A. R. Lindley, H. E. Ambrose, A. S. Malin, and A. E. Wakefield Genotypes of Pneumocystis jiroveci Isolates Obtained in Harare, Zimbabwe, and London, United Kingdom Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3979 - 3981. [Abstract] [Full Text] [PDF]

				T. Lipman, D. Price, and T. Greenhalgh Decision making, evidence, audit, and education: case study of antibiotic prescribing in general practice Commentary: What can we learn from narratives of implementing evidence? BMJ, April 22, 2000; 320(7242): 1114 - 1118. [Abstract] [Full Text]